The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer

International Urology and Nephrology

Volumn 44, Issue 6, 2012, Pages 1681-1689

  Al Maghrebi, May ^a   Kehinde, Elijah O ^a   Anim, Jehoram T ^a   Sheikh, Mehraj ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

AMACR; Prostate cancer; Real time PCR; Risk factor; Survivin; Tissue molecular markers

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; SURVIVIN; ALPHA-METHYLACYL-COA RACEMASE; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; ISOMERASE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL; TRANSRECTAL ULTRASONOGRAPHY; BIOPSY; CHEMISTRY; GENETICS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; RISK ASSESSMENT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; RISK ASSESSMENT; RNA, MESSENGER;

EID: 84877625868     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0220-2     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. (2009) Cancer statistics. CA Cancer J Clin 59:225-249
2. Etzioni R, Penson DF, Legler JM, et al. (2002) Overdiagnosis due prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 94:981-990
3. Bastian PJ, Carter BH, Bjartell A, et al. (2009) Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 55:1321-1332
4. Pound CR, Partin AW, Eisenberger MA, et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597
5. Han M, Partin AW, Zahurak M, et al. (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523
6. Sardena G, Dowell B, Diamandis EP (2008) Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 54:1951-1960
7. Fradet Y (2009) Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate specific antigen. Curr Opin Urol 19:243-246
8. Fiorentino M, Capizzi E, Loda M (2010) Biomarkers in prostate cancer: state of the art. Urol Clin N Am 37:131-141
9. Xu J, Stolk JA, Zhang X, et al. (2000) Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 60:1677-1682
10. Stewart J, Fleshner N, Cole H, et al. (2008) Prognostic significance of alpha-methyl-Co a racemase among men with high grade PIN in prostate biopsies. J Urol 179:1751-1755
11. Shariat SF, Lotan Y, Saboorian H, et al. (2004) Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100:751-757
12. Ferdinandusse S, Denis S, IJlst L, et al. (2000) Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 41:1890-1896
13. Rubin MA, Zhou M, Dhanasekaran SM, et al. (2002) Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287:1662-1670
14. Jiang Z, Woda BA, Wu C, et al. (2004) Discovery and clinical application of a novel prostate cancer marker α-methylacyl CoA racemase (P504S). Am J Clin Pathol 122:275-289
15. Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542-547
16. Adida C, Crotty PL, McGrath J, et al. (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43-49
17. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921
18. Kishi H, Igawa M, Kikuno N, et al. (2004) Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171:1855-1860
19. Jiang Z, Woda BA, Rock KL, et al. (2001) P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25:1397-1404
20. Presti JC (2007) Prostate biopsy: current status and limitations. Rev Urol 9:93-98
21. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408
22. Luo J, Zha S, Gage WR, et al. (2002) Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62:2220-2226
23. Beach R, Gown AM, De Peralta-Venturina MN, et al. (2002) P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 26:1588-1596
24. Rogers CG, Yan G, Zha S, et al. (2004) Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol 172:1501-1503
25. Zielie PJ, Mobley JA, Ebb RG, et al. (2004) A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions. J Urol 172:1130-1133
26. Zehentner BK, Secrist H, Zhang X, et al. (2006) Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients. Mol Diagn Ther 10:397-403
27. Kuefer R, Varambally S, Zhou M, et al. (2002) Alphamethylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumour differentiation. Am J Pathol 161:841-848
28. Schostak M, Miller K, Krause H, et al. (2006) Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions. Cancer Detect Prev 30:449-454
29. Xing N, Qian J, Bostwick D, et al. (2001) Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 48:7-15
30. Shariat SF, Ashfaq R, Roehrborn CG, et al. (2005) Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol 174:2046-2050
31. Kaur P, Kallakury BS, Sheehan CE, et al. (2004) Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 128:39-43
32. Nesrallah L, Nesrallah A, Antunes AA, et al. (2008) The role of extended prostate biopsy on prostate cancer detection rate: a study performed on the bench. Int Braz J Urol 34:563-570
33. Etzioni R (2008) Statistical issues in the evaluation of screening and early detection modalities. Urol Oncol 26:308-315
34. Stamey TA, Caldwell M, McNeal JE, et al. (2004) The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172:1297-1301